- Trials with a EudraCT protocol (437)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
437 result(s) found for: Active lifestyle.
Displaying page 8 of 22.
EudraCT Number: 2007-000240-27 | Sponsor Protocol Number: 01-06-TL-SYR472-007 | Start Date*: 2007-05-25 | |||||||||||
Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd | |||||||||||||
Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate Weekly Treatment with SYR-472 in Subjects with Type 2 Diabetes. | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Completed) HU (Completed) LT (Completed) CZ (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002938-73 | Sponsor Protocol Number: ARGX-113-1602 | Start Date*: 2016-10-31 | |||||||||||
Sponsor Name:Argenx BVBA | |||||||||||||
Full Title: A Randomized, Double blind, Placebo Controlled Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX 113 in Patients with Myasthenia Gravis who have Generalized Muscle Weakness | |||||||||||||
Medical condition: Myasthenia Gravis who have Generalized Muscle Weakness | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) SE (Completed) ES (Completed) NL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001578-27 | Sponsor Protocol Number: ABX464-302 | Start Date*: 2019-10-15 | |||||||||||
Sponsor Name:Abivax | |||||||||||||
Full Title: A follow-up Phase 2a open-label study to evaluate the long-term safety and efficacy profile of ABX464 in patients with moderate to severe active Rheumatoid Arthritis. | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001991-39 | Sponsor Protocol Number: NIR-DT-301 | Start Date*: 2019-07-26 |
Sponsor Name:SpringWorks Subsidiary 2, PBC | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients with Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF). | ||
Medical condition: Desmoid Tumors/Aggressive Fibromatosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) NL (Completed) DE (Completed) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003113-94 | Sponsor Protocol Number: M16-244 | Start Date*: 2016-12-01 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: Phase 2 Single-Arm Open-Label Extension Study to Investigate Safety with Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study 1311.5 | |||||||||||||
Medical condition: Psoriatic Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) FI (Completed) ES (Completed) BE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003398-91 | Sponsor Protocol Number: ABI-007-PANC-003 | Start Date*: 2014-05-15 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A Phase 3, Multicenter, Open-label, Randomized Study of nab-Paclitaxel Plus Gemcitabine versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma | |||||||||||||
Medical condition: Subjects With Surgically Resected Pancreatic Adenocarcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) AT (Completed) HU (Completed) ES (Ongoing) IT (Completed) PT (Completed) BE (Completed) FI (Completed) IE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-005261-38 | Sponsor Protocol Number: AVS00103 | Start Date*: 2005-10-04 | |||||||||||
Sponsor Name:Genzyme Europe BV | |||||||||||||
Full Title: A Multicenter, Parallel, Double-Blind, Blinded Evaluator, Randomized Comparison of the Efficacy and Safety of an Alternate Viscosupplement (AVS-beta) to Methylprednisolone Acetate in Patients with ... | |||||||||||||
Medical condition: Osteoarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000399-13 | Sponsor Protocol Number: Uni-Koeln-3254 | Start Date*: 2019-03-08 | |||||||||||
Sponsor Name:University of Cologne | |||||||||||||
Full Title: A phase II trial to evaluate efficacy and safety of erdafitinib in patients with advanced NSCLC harbouring FGFR genetic alterations after relapse of standard therapy | |||||||||||||
Medical condition: •Stage IIIB/IV NSCLC patients with activating FGFR alteration after the failure of ≥ 1st line standard therapy •Activating FGFR alteration as defined by FIND Molecular Board •ECOG performance sta... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002485-32 | Sponsor Protocol Number: CTRIAL-IE-22-01 | Start Date*: 2023-03-07 | |||||||||||
Sponsor Name:Cancer Trials Ireland | |||||||||||||
Full Title: Single arm phase 2 trial of neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a standard chemotherapy-sparing approach... | |||||||||||||
Medical condition: HER2-positive breast cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004495-60 | Sponsor Protocol Number: I4V-MC-JAHU | Start Date*: 2019-09-24 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Withdrawal, Safety and Efficacy Study of Oral Baricitinib in Patients from 1 Year to Less than 18 Years Old with Systemic Juvenile Idiopathic Arthrit... | |||||||||||||
Medical condition: Systemic Juvenile Idiopathic Arthritis (sJIA) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Prematurely Ended) AT (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) PL (Trial now transitioned) DK (Prematurely Ended) ES (Ongoing) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-000944-82 | Sponsor Protocol Number: MK-3475-966 | Start Date*: 2020-03-05 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants with Advanced and/or Unresectabl... | |||||||||||||
Medical condition: Advanced and/or Unresectable Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, or Gallbladder) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) IE (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004547-21 | Sponsor Protocol Number: ZP4207-17109 | Start Date*: 2018-08-24 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: A Two-Period, Open-label Trial Evaluating the Efficacy and Safety of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism | |||||||||||||
Medical condition: Children with congenital hyperinsulinism | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000789-13 | Sponsor Protocol Number: Trial_version1 | Start Date*: 2013-07-05 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: Vitamin D And Lifestyle Intervention for Gestational Diabetes Mellitus (GDM) Prevention - A European multicentre, randomised trial: Vitamin D limb. | |||||||||||||
Medical condition: Gestational diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002945-39 | Sponsor Protocol Number: CM-101-PSC-101 | Start Date*: 2020-04-15 | |||||||||||
Sponsor Name:ChemomAb Ltd | |||||||||||||
Full Title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial Evaluating the Safety and Efficacy of CM-101 in Subjects with Primary Sclerosing Cholangitis | |||||||||||||
Medical condition: Primary Sclerosing Cholangitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002588-24 | Sponsor Protocol Number: B1971060 | Start Date*: 2021-06-16 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 4, OPEN-LABEL, SINGLE-ARM TRIAL TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF TRUMENBA® WHEN ADMINISTERED TO IMMUNOCOMPROMISED PARTICIPANTS ≥10 YEARS OF AGE | |||||||||||||
Medical condition: prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004546-15 | Sponsor Protocol Number: ZP4207-17106 | Start Date*: 2018-08-24 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism | |||||||||||||
Medical condition: Children with congenital hyperinsulinism | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-002633-38 | Sponsor Protocol Number: 08781 | Start Date*: 2018-11-19 |
Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust | ||
Full Title: An open label phase I/IIa trial repurposing carbamazepine (CBZ) for the treatment of skeletal dysplasia in children. | ||
Medical condition: Metaphyseal chondrodysplasia type Schmid (MCDS) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001323-12 | Sponsor Protocol Number: PEVOLAM | Start Date*: 2020-09-23 | |||||||||||
Sponsor Name:Fundación PETHEMA | |||||||||||||
Full Title: A randomized phase III, multicentre, open label clinical trial comparing azacitidine plus pevonedistat versus azacitidine in Older/Unfit patients with newly diagnosed acute myeloid leukemia who are... | |||||||||||||
Medical condition: Acute Myeloid Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004291-18 | Sponsor Protocol Number: 54135419TRD4010 | Start Date*: 2021-04-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: Open-label Long-Term Extension Study for Participants With Treatment-Resistant Major Depressive Disorder Who are Continuing Esketamine Nasal Spray Treatment From Study 54135419TRD3013 | |||||||||||||
Medical condition: Treatment-Resistant Major Depressive Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) CZ (Completed) HU (Completed) PL (Completed) BG (Completed) FI (Completed) GR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-003693-31 | Sponsor Protocol Number: C3671013 | Start Date*: 2021-09-30 | |||||||||||
Sponsor Name:Pfizer Inc., 66 Hudson Boulevard East New York, NY 10001 | |||||||||||||
Full Title: A PHASE 3 STUDY TO EVALUATE THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN ADULTS | |||||||||||||
Medical condition: Prevention of RSV-associated lower respiratory tract illness in adults 60 years of age and older by active immunization | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) NL (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
